On Friday, Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), added 1.25% and closed at $5.69 in the last trading session. The last trading range of the stock ranges between $5.56 and $5.74. The company’s Market capitalization is $758.89 Billion with the total Outstanding Shares of 131.73Billion. During the 52-week trading session the minimum price at which share price traded, registered at $4.45 and reached to max level of $14.93. ZIOPHARM Oncology, Inc. (ZIOP) declared the presentation of preliminary data from the Company’s Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The poster presentation, titled “Phase 1b/2 study of intratumoral Ad-RTS-hIL-12+veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer,” was presented at the European Society for Medical Oncology (ESMO) 2016 Congress recently in Copenhagen, Denmark.
The study, which is being conducted at the Memorial Sloan Kettering Cancer Center in New York, is designed to examine the safety, tolerability and efficacy of Ad-RTS-hIL-12 immunotherapy in up to 40 women with locally advanced or metastatic breast cancer of all subtypes. Ad-RTS-hIL-12 + veledimex is a novel gene therapy which controls local expression of IL-12. The ability to regulate the production of IL-12 by modulating veledimex dosing is designed to improve its therapeutic index with standard of care.
Following entry into the trial, patients go on a chemotherapy holiday and enter an immunotherapy phase of treatment. A single cycle of Ad-RTS-hIL-12, together with the oral activator ligand veledimex, is given during the immunotherapy phase, with the aim of maintaining or improving pre-study response.
As of August 30, 2016, a total of nine patients were available for initial assessment. Results show that Ad-RTS-hIL-12 + 7 days of veledimex consistently elicited production of IL-12 which in turn produced IFNγ. It was notable that the intratumoral influx of CD8+ T cells and IFNγ were present six weeks after completion of veledimex consistent with the ability of Ad-RTS-hIL-12 to favorably impact the tumor environment over the long term. In two patients, Ad-RTS-hIL-12 + veledimex offered a meaningful drug holiday, with durable responses for 18 and 35 weeks. In all patients, disease control rate (DCR) was 44% at Week 6 and 22% at Week 12. Overall response rate (ORR), defined as achieving a partial response (PR) or better, was 11% at Week 12. Most toxicities promptly reversed upon discontinuation of veledimex, counting cytokine release syndrome (grade 1-2 CRS), observed in six of nine patients. The higher than expected incidence of CRS was likely related to CYP-3A4 drug interactions with veledimex (80 mg) which resulted in improved peak cytokine expression.
Shares of Helen of Troy Limited (NASDAQ:HELE), subtract -7.11% and closed at $80.69 in the last trading session. The last trading range of the stock ranges between $80.21 and $85.41. The company’s Market capitalization is $2.09 Billion with the total Outstanding Shares of 27.84 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $80.21 and reached to max level of $106.50. Helen of Troy Limited (NASDAQ, NM: HELE), designer, developer and worldwide marketer of consumer brand-name housewares, health and home, nutritional supplement and beauty products, recently stated results for the three-month period ended August 31, 2016.
Merged net sales decline of 0.3%, which includes the negative impacts of about 1.6% from Venezuela, 0.6% from foreign currency fluctuations and 2.1% from business rationalization;
Hydro Flask net sales of $29.1 million and diluted EPS of $0.32;
Increase in merged gross profit margin of 4.2 percentage points; 2.6 percentage points from the core business;
Stated operating income of $37.5 million, or 10.2% of net sales, contrast to $32.4 million, or 8.8% of net sales in the same period last year;
Non-GAAP adjusted operating income of $47.9 million contrast to $41.5 million in the same period last year, a boost in adjusted operating margin of 1.8 percentage points;
Cash flow from operations of $44.0 million contrast to $14.4 million in the same period last year;
Stated diluted EPS of $1.00 raised 19.0% from $0.84 in the same period last year;
Non-GAAP adjusted diluted EPS of $1.31 raised 17.0% from $1.12 in the same period last year;
Adjusts fiscal year 2017 net sales revenue to a range of $1.550 to $1.590 billion from a range of $1.570 billion to $1.620 billion; and
Maintains GAAP diluted EPS in a range of $4.37 to $4.77 and non-GAAP adjusted diluted EPS in a range of $5.85 to $6.35.